Expression of Concern: Role of LOX/COX pathways in 3-nitropropionic acid-induced Huntington's Disease-like symptoms in rats: protective effect of licofelone (British Journal of Pharmacology, (2011), 164, 2b, (644-654), 10.1111/j.1476-5381.2011.01418.x);Role of LOX/COX pathways in 3-nitropropionic acid-induced Huntington's Disease-like symptoms in rats: Protective effect of licofelone

British Journal of Pharmacology

Volumn 164, Issue 2 B, 2011, Pages 644-654

  Kumar, Puneet ^a   Kalonia, Harikesh ^a   Kumar, Anil ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

3 nitropropionic acid; caspase 3; licofelone; mitochondria; NF B; oxidative stress; striatum; TNF

Indexed keywords

3 NITROPROPIONIC ACID; CASPASE 3; CATALASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LICOFELONE; LIPOXYGENASE; MALONALDEHYDE; MITOCHONDRIAL ENZYME; NITRITE; PLACEBO; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN SYNTHASE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CORPUS STRIATUM; DRUG DOSE COMPARISON; ENCEPHALITIS; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME METABOLISM; HUNTINGTON DISEASE LIKE SYNDROME; LIPID PEROXIDATION; LOCOMOTION; MALE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RAT; ROTAROD TEST; WEIGHT REDUCTION;

EID: 80052192028     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.14655     Document Type: Erratum

References (52)

1. Arai K, Nishiyama N, Matsuki N, Ikegaya Y, (2001). Neuroprotective effects of lipoxygenase inhibitors against ischemic injury in rat hippocampal slice cultures. Brain Res 904: 167-172. (Pubitemid 32545369)
2. Arzberger T, Krampfl K, Leimgruber S, Weindl A, (1997). Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington's disease-an in situ hybridization study. J Neuropathol Exp Neurol 56: 440-454. (Pubitemid 27465027)
3. Berman SB, Hastings TG, (1999). Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J Neurochem 73: 1127-1137. (Pubitemid 29395471)
4. Bishnoi M, Patil CS, Kumar A, Kulkarni SK, (2005). Protective effects of nimesulide (COX Inhibitor), AKBA (5-LOX Inhibitor), and their combination in aging-associated abnormalities in mice. Methods Find Exp Clin Pharmacol 27: 465-470. (Pubitemid 41444974)
5. Bishnoi M, Patil CS, Kumar A, Kulkarni SK, (2006). Potentiation of antinociceptive effect of NSAIDs by a specific lipooxygenase inhibitor, acetyl 11-keto-beta boswellic acid. Indian J Exp Biol 44: 128-132. (Pubitemid 43219168)
6. Bishnoi M, Patil CS, Kumar A, Kulkarni SK, (2007). Co-administration of acetyl-11-keto-beta-boswellic acid, a specific 5-lipoxygenase inhibitor, potentiates the protective effect of COX-2 inhibitors in kainic acid-induced neurotoxicity in mice. Pharmacology 79: 34-41. (Pubitemid 46034175)
7. Bizat N, Hermel JM, Humbert S, Jacquard C, Creminon C, Escartin C, et al,. (2003). In vivo calpain/caspase cross-talk during 3-nitropropionic acid-induced striatal degeneration: implication of a calpain-mediated cleavage of active caspase-3. J Biol Chem 278: 43245-43253. (Pubitemid 37345944)
8. Borlongan CV, Koutouzis TK, Sanberg PR, (1997). 3-Nitropropionic acid animal model and Huntington's disease. Neurosci Biobehav Rev 21: 289-293. (Pubitemid 27225151)
9. Brouillet E, Jenkins BG, Hyman BT, Ferrante RJ, Kowall NW, Srivastava R, et al,. (1993). Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J Neurochem 60: 356-359. (Pubitemid 23006739)
10. Brouillet E, Condé F, Beal MF, Hantraye P, (1999). Replicating Huntington's disease phenotype in experimental animals. Prog Neurobiol 59: 427-468. (Pubitemid 29392967)
11. Browne SE, Ferrante RJ, Beal MF, (1999). Oxidative stress in Huntington's disease. Brain Pathol 9: 147-163. (Pubitemid 29056525)
12. Coles CJ, Edmondson DE, Singer TP, (1979). Inactivation of succinate dehydrogenase by 3-nitropropionate. J Biol Chem 254: 5161-5167.
13. Fosslien E, (2005). Cardiovascular complications of non-steroidal anti-inflammatory drugs. Ann Clin Lab Sci 35: 347-385. (Pubitemid 41581673)
14. Gil JM, Rego AC, (2008). Mechanisms of neurodegeneration in Huntington's disease. Eur J Neurosci 27: 2803-2820. (Pubitemid 351832229)
15. Gornall AG, Bardawill CJ, David MM, (1949). Determination of serum proteins by means of the biuret reaction. J Biol Chem 177: 751-766.
16. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR, (1982). Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Ann Biochem 126: 131-138. (Pubitemid 13203451)
17. Hurley SD, Olschowka JA, O'Banion MK, (2002). Cyclooxygenase inhibition as a strategy to ameliorate brain injury. J Neurotrauma 19: 1-15. (Pubitemid 34117092)
18. Kalonia H, Kumar P, Kumar A, Nehru B, (2009a). Effect of caffeic acid and rofecoxib and their combination against intrastriatal quinolinic acid induced oxidative damage, mitochondrial and histological alterations in rats. Inflammopharmacology 17: 211-219.
19. Kalonia H, Kumar P, Nehru B, Kumar A, (2009b). Neuroprotective effect of MK-801 against intra-striatal quinolinic acid induced behavioral, oxidative stress and cellular alterations in rats. Indian J Exp Biol 47: 880-892.
20. Kalonia H, Kumar P, Kumar A, Nehru B, (2009c). Effects of caffeic acid, rofecoxib, and their combination against quinolinic acid-induced behavioral alterations and disruption in glutathione redox status. Neurosci Bull 25: 343-352.
21. Kalonia H, Kumar P, Kumar A, Nehru B, (2010). Protective effect of rofecoxib and nimesulide against intra-striatal quinolinic acid-induced behavioral, oxidative stress and mitochondrial dysfunctions in rats. Neurotoxicology 31: 195-203.
22. Keller JN, Guo Q, Holtsberg FW, Bruce-Keller AJ, Bruce-Keller AJ, Mattson MP, (1998). Increased sensitivity to mitochondrial toxin-induced apoptosis in neural cells expressing mutant presenilin-1 is linked to perturbed calcium homeostasis and enhanced oxyradical production. J Neurosci 18: 4439-4450. (Pubitemid 28280155)
23. King TE, (1967). Preparation of succinate dehydrogenase and reconstitution of succinate oxidase. Methods Enzymol 10: 322-331.
24. King TE, Howard RL, (1967). Preparations and properties of soluble NADH dehydrogenases from cardiac muscle. Methods Enzymol 10: 275-284.
25. Kono Y, (1978). Generation of superoxide radical during auto-oxidation of hydroxylamine and an assay of superoxide dismutase. Arch Biochem Biophys 186: 189-195. (Pubitemid 8290500)
26. Kulkarni SK, Singh VP, (2007). Licofelone-a novel analgesic and anti-inflammatory agent. Curr Top Med Chem 7: 251-263. (Pubitemid 46358659)
27. Kulkarni SK, Singh VP, (2008). Licofelone: the answer to unmet needs in osteoarthritis therapy? Curr Rheumatol Rep 10: 43-48.
28. Kumar P, Kumar A, (2008). Prolonged pretreatment with carvedilol prevents 3-nitropropionic acid-induced behavioral alterations and oxidative stress in rats. Pharmacol Rep 60: 706-715.
29. Kumar P, Kumar A, (2009a). Effect of lycopene and epigallocatechin-3- gallate against 3-nitropropionic acid induced cognitive dysfunction and glutathione depletion in rat: a novel nitric oxide mechanism. Food Chem Toxicol 47: 2522-2530.
30. Kumar P, Kumar A, (2009b). Possible neuroprotective effect of Withania somnifera root extract against 3-nitropropionic acid-induced behavioral, biochemical, and mitochondrial dysfunction in an animal model of Huntington's disease. J Med Food 12: 591-600.
31. Kumar P, Kumar A, (2009c). Protective effect of rivastigmine against 3-nitropropionic acid-induced Huntington's disease like symptoms: possible behavioural, biochemical and cellular alterations. Eur J Pharmacol 615: 91-101.
32. Kumar P, Kumar A, (2009d). Possible role of sertraline against 3-nitropropionic acid induced behavioral, oxidative stress and mitochondrial dysfunctions in rat brain. Prog Neuropsychopharmacol Biol Psychiatry 33: 100-108.
33. Kumar P, Kumar A, (2009e). Neuroprotective effect of cyclosporine and FK506 against 3-nitropropionic acid induced cognitive dysfunction and glutathione redox in rat: possible role of nitric oxide. Neurosci Res 63: 302-314.
34. Kumar P, Padi SS, Naidu PS, Kumar A, (2006). Effect of resveratrol on 3-nitropropionic acid-induced biochemical and behavioural changes: possible neuroprotective mechanisms. Behavioural Pharmacology 17: 485-492. (Pubitemid 44325810)
35. Kumar P, Padi SS, Naidu PS, Kumar A, (2007). Cyclooxygenase inhibition attenuates 3-nitropropionic acid-induced neurotoxicity in rats: possible antioxidant mechanisms. Fundam Clin Pharmacol 21: 297-306. (Pubitemid 46800477)
36. Liot G, Bossy B, Lubitz S, Kushnareva Y, Sejbuk N, Bossy Wetzel E, (2009). Complex-II inhibition by 3-NP causes mitochondrial fragmentation and neuronal cell death via an NMDA- and ROS-dependent pathway. Cell Death Differ 16: 899-909.
37. Liu Y, Peterson DA, Kimura H, Schubert D, (1997). Mechanisms of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolinium bromide (MTT) reduction. J Neurochem 69: 581-593. (Pubitemid 27327958)
38. Luck H, (1971). Catalase. In:, Bergmeyer HU, (ed.). Methods of Enzymatic Analysis. Academic Press: New York, pp. 885-893.
39. Ludolph AC, He F, Spencer PS, Hammerstad J, Sabri M, (1991). 3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin. Can J Neurol Sci 18: 492-498.
40. Meffert MK, Baltimore D, (2005). Physiological functions for brain NF-κβ. Trends Neurosci 28: 37-43.
41. Mrak RE, Griffin WS, (2005). Potential inflammatory biomarkers in Alzheimer's disease. J Alzheimers Dis 8: 369-375.
42. Portera-Cailliau C, Hedreen JC, Price DL, Koliatsos VE, (1995). Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models. J Neurosci 15: 3775-3787.
43. Qu T, Uz T, Manev H, (2000). Inflammatory 5-LOX mRNA and protein are increased in brain of aging rats. Neurobiol Aging 21: 647-652.
44. Singh VP, Patil CS, Kulkarni SK, (2005a). Effect of licofelone against mechanical hyperalgesia and cold allodynia in the rat model of incisional pain. Pharmacol Rep 57: 380-384. (Pubitemid 41030699)
45. Singh VP, Patil CS, Kulkarni SK, (2005b). Effect of licofelone against NSAIDs-induced gastrointestinal ulceration and inflammation. Indian J Exp Biol 43: 247-253. (Pubitemid 40367993)
46. Singh VP, Patil CS, Kulkarni SK, (2006). Anti-inflammatory effect of licofelone against various inflammatory challenges. Fundam Clin Pharmacol 20: 65-71.
47. Sottocasa GL, Kuylenstierna B, Ernster L, Bergstrand A, (1967). An electron-transport system associated with the outer membrane of liver mitochondria. A biochemical and morphological study. J Cell Biol 32: 415-438.
48. Tobinick EL, Gross H, (2008). Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. J Neuroinflammation 5: 2.
49. Tunez I, Collado JA, Medina FJ, Pena J, Del CMM, Jimena I, et al,. (2006). 17 β-Estradiol may affect vulnerability of striatum in a 3-nitropropionic acid-induced experimental model of Huntington's disease in ovariectomized rats. Neurochem Int 48: 367-373. (Pubitemid 43327276)
50. Vidal C, Gomez-Hernandez A, Sanchez-Galan E, Gonzalez A, Ortega L, Gomez-Gerique JA, et al,. (2007). Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis. J Pharmacol Exp Ther 320: 108-116. (Pubitemid 46025725)
51. Wills ED, (1966). Mechanisms of lipid peroxide formation in animal tissues. Biochem J 99: 667-676.
52. Yang L, Sugama S, Mischak RP, Kiaei M, Bizat N, Brouillet E, et al,. (2004). A novel systemically active caspase inhibitor attenuates the toxicities of MPTP, malonate, and 3NP in vivo. Neurobiol Dis 17: 250-259. (Pubitemid 39345780)